Cytosorbents Corporation - Common Stock (CTSO)

CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device.

CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group.

CTSO stock results show that CytoSorbents met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90. The S&P 500 also rose, gaining, 0.23% to 4,792.56.

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Thursday. The Dow traded up 0.14% to 37,708.15 while the NASDAQ rose 0.19% to 15,127.17. The S&P 500 also rose, gaining, 0.14% to 4,788.28.

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 37,708.72 while the NASDAQ rose 0.15% to 15,122.12. The S&P 500 also rose, gaining, 0.18% to 4,790.25.

CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S.